LLY Jun 2024 240.000 call
| Previous Close | 225.65 |
| Open | 225.65 |
| Bid | 319.50 |
| Ask | 323.80 |
| Strike | 240.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 225.65 - 225.65 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 12 |
ReutersEli Lilly settles whistleblower lawsuit over manufacturing problems
Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings. The former human resources officer, Amrit Mula, contended in the lawsuit that she repeatedly urged leaders at a New Jersey plant to remedy problems involving several biologic drugs, including Type 2 diabetes medicine Trulicity. Lilly called Mula a non-scientist whose allegations were "simply wrong," according to court filings.
ZacksNektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
- Reuters
INSIGHT-Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts
“I knew it was the drug,” said Heidlebaugh, who said she had not previously suffered from depression. Heidlebaugh is one of four U.S. patients who told Reuters about experiencing suicidal thoughts while taking Novo Nordisk’s popular Ozempic drug, approved to treat type 2 diabetes, or Wegovy, another Novo top-seller approved for weight loss. A fifth patient said he experienced depression and suicidal thoughts after taking Mounjaro, a similar diabetes medicine from Eli Lilly, which is also used for weight loss.
